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Abstract
Background: Neuropsychiatric conditions comprise 14% of the global burden of disease and 30% of all noncommunicable
disease. Despite the existence of cost-effective interventions, including administration of psychotropic medicines, the
number of persons who remain untreated is as high as 85% in low- and middle-income countries (LAMICs). While access to
psychotropic medicines varies substantially across countries, no studies to date have empirically investigated potential
health systems factors underlying this issue.
Methods and Findings: This study uses a cross-sectional sample of 63 LAMICs and country regions to identify key health
systems components associated with access to psychotropic medicines. Data from countries that completed the World
Health Organization Assessment Instrument for Mental Health Systems (WHO-AIMS) were included in multiple regression
analyses to investigate the role of five major mental health systems domains in shaping medicine availability and
affordability. These domains are: mental health legislation, human rights implementations, mental health care financing,
human resources, and the role of advocacy groups. Availability of psychotropic medicines was associated with features of all
five mental health systems domains. Most notably, within the domain of mental health legislation, a comprehensive
national mental health plan was associated with 15% greater availability; and in terms of advocacy groups, the participation
of family-based organizations in the development of mental health legislation was associated with 17% greater availability.
Only three measures were related with affordability of medicines to consumers: level of human resources, percentage of
countries’ health budget dedicated to mental health, and availability of mental health care in prisons. Controlling for
country development, as measured by the Human Development Index, health systems features were associated with
medicine availability but not affordability.
Conclusions: Results suggest that strengthening particular facets of mental health systems might improve availability of
psychotropic medicines and that overall country development is associated with affordability.
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Access to treatments for mental disorders is inadequate in a
large majority of low- and middle-income countries (LAMICs).
The percentage of individuals who have severe disorders such as
schizophrenia, bipolar disorder, and major depressive disorder,
but who remain untreated, is estimated to be as high as 85% in
these settings [1]. This so-called ‘‘treatment gap’’ is particularly
disconcerting when the prevalence and debilitating impacts of
these illnesses are taken into account. Approximately 450 million
people worldwide have a mental illness, as such accounting for an
estimated one-third of all years lived with disability [2,3]. Coupled
with severity of associated symptoms, mental disorders comprise
approximately 13.5% of the global burden of disease (GBD) [4]
and 30% of the noncommunicable disease burden worldwide [5].
Roughly 80% of persons with mental illnesses live in LAMICs
[4]. However, in part because of high rates of infectious diseases,
those countries that are the poorest typically spend the least on
mental health and rely upon a framework of institutionalized care
[6,7]. For example, only 52% of low-income countries, as
compared to 97% of high-income countries, provide communi-
ty-based care for patients [8]. This dearth of financial resources
directed towards mental health is also associated with a shortage of
human resources trained in mental health care, ranging from
levels of primary to tertiary care [9–11].
A burgeoning literature is developing on the efficacy and cost-
effectiveness of specific treatment interventions [12,13]. In terms of
efficacy, studies have shown that both psychosocial and pharma-
cological interventions are effective in treating major depressive
disorder [14–21], schizophrenia [22–25], alcohol dependence
[26–29], and developmental disabilities [30–35]. In terms of the
cost-effectiveness of interventions in LAMIC settings, one recent
systematic review found over 450 trials on the utility of first
generation antipsychotic drugs for the treatment of schizophrenia,
in addition to more than 200 trials on tricyclic antidepressants for
major depressive disorder, both of which are stated as cost-
effective by the Disease Control Priorities Project [36]. Neverthe-
less, access to medicines—both in terms of availability and
affordability—is exceedingly limited in LAMIC settings, and only
a small number of studies have critically analyzed access to
psychotropic medicines in LAMICs. At the conceptual level,
inadequate and poorly distributed financial resources [37], a
shortage of human resources [38,39], and overregulation due to
the potential for abuse of certain drugs [40] have been highlighted
as significant impediments to access. In addition, country-specific
analyses have identified contextual shortcomings such as inade-
quate human resources training [41,42] and cultural norms and
perceptions of mental illness [43–46].
A foremost challenge in improving access to psychotropic
medicines is bringing a conceptual perspective of what should, in
theory, work to bear on the context-specific situations of individual
countries. Cross-national analyses that take into account empirical
data relating aspects of mental health care systems—for example,
number of health workers, government mental health policies, and
involvement of different stakeholders—may serve to shed light on
target areas that should be prioritized for improvement. One
method for achieving this improvement would be to approach the
issue of access to psychotropic drugs from a health systems
perspective.
Assuming a health systems approach to understanding and
addressing mental health care entails an evaluation of the
country-level framework and the major building blocks liable to
affect treatment coverage [47]. According to the World Health
Organization Assessment Instrument for Mental Health Systems
(WHO-AIMS), these building blocks include leadership and
governance, the distribution of human resources for mental
health, a system of health services delivery, a scheme for
financing and appropriating resources, access to treatments
including a human rights framework to protect patients, and an
information systems to collect data and monitor performance
over time [48]. While each health system is context-specific,
health systems that function well tend to share certain basic
characteristics [49]. For example, while the content of a national
mental health plan should be expected to vary according to
unique needs within a country, it is fundamental that all countries
have a plan that contains actionable items monitored and
evaluated over time [47,50,51].
This study utilizes data from 63 developing countries or country
regions—representing approximately 1.9 billion people world-
wide—to identify associations with access to and affordability of
psychotropic medicines across five health systems domains. For the
purposes of these analyses, domains are defined in terms of: mental
health legislation, human rights training and inspection, financing,
level of human resources working within mental health facilities,
and mental health advocacy and promotion by a variety of
stakeholders. To date, a cross-national cross-sectional analysis of
this kind has not been conducted.
Methods
Respondent Sample
Sixty-three countries or country regions that completed the
WHO-AIMS before June 2010 were included in the study. Of the
63 LAMICs, 58 provided sufficient information on availability of
psychotropic medicines and 54 on affordability. Comparing
countries with and without sufficient information, there were no
significant differences in terms of gross national income (GNI) per
capita, level of specificity in mental health legislation or overall
rates of human resources (p.0.05 in each instance), indicating that
these subsamples were not characteristically biased.
WHO-AIMS was created in 2004 as a tool for enabling
LAMICs to evaluate core components of their mental health
systems, with the ultimate goal of providing critical information for
the strengthening of mental health policies and service delivery
[48]. The instrument comprises 155 items across six health systems
domains (outlined above). Items are quantitative, defined as
numbers, rates, proportions, and ordinal scales, and predominate-
ly represent process rather than outcome measures. Data are
collected by country-based focal points, often within countries’
Ministries of Health, and are evaluated and revised through an
iterative process in conjunction with WHO headquarters in
Geneva, Switzerland. A set of instructions and operational
definitions are also provided by WHO headquarters. A full
overview of the data collection process and instrument content is
available at the WHO’s WHO-AIMS web page [52].
In eight datasets—Hunan Province, China; Uttarakhand State,
India; Gujarat State, India; South Central Somalia; Somaliland
Somalia; Anguilla; Kosovo; and West Bank and Gaza—the data
are representative of specific country regions or territories. Thus,
in two countries, India and Somalia, two datasets were included
for a single country. In the case of India—a country comprising
approximately 1.2 billion citizens—a single measure cannot
characterize the level of heterogeneity observed across relatively
decentralized states. In the case of Somalia, ongoing civil war has
left the nation largely divided, with Somaliland considered a
separatist region that maintains its own governing body. For the
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countries, while acknowledging that the reality is more subtle [53].
This study includes 15 low-income, 36 lower-middle income, and
13 upper-middle income countries according to current World
Bank classifications [54]. Additional descriptive characteristics of
the sample, including summary measures of availability and
affordability of psychotropic medicines, are provided in Table 1.
Health System Domain Measures
The five health system domains assessed in this study map
closely to the conceptual framework outlined in WHO-AIMS and
WHO Mental Health Atlas instruments and represent core
content areas of most well-functioning systems. Within each of
the five mental health systems domains, indicators that were
thought to be theoretically related to medicine access on the basis
of the existing literature, that were representative of overarching
constructs, and that did not contain significant missingness (i.e.,
roughly 90% or more of participating countries provided data)
were identified for investigation. Owing to limited sample size,
only one to three summary measurements per health systems
domain were included in order to prevent overspecificity in model
fitting.
Domain 1: Legislation. The WHO-AIMS instrument
contains information on both the existence and contents of
national mental health policies, plans, and laws. Preliminary
analyses using bivariate associations revealed that the specificity of
content within mental health policies and plans were closely
related. On the basis of the stronger implementation focus of plans
as compared to policies, specificity of national plans was selected as
the more relevant measure. As there were 12 content areas
identified for national mental health plans, a summary score was
created such that countries’ scores could range from 0 (no mental
health plan) to 12 (all content areas addressed). The associated
Cronbach’s alpha of this scale—a measure of internal
consistency—was a=0.96, connoting strong consistency of
responses across items. In a similar vein, content of mental
health laws comprised eight content items and were integrated into
a scale of 0 to 8 (a=0.95).
Domain 2: Human rights. Respondents to the WHO-
AIMS are asked to identify whether the country inspects human
rights violations at mental hospitals and at community-based
inpatient psychiatric units, as well as whether staff at both types of
facilities are trained on the human rights protections of patients.
Human rights inspection and training were strongly interrelated;
as such, a composite measure for human rights implementations
was created, whereby countries could score from 0% (no human
rights inspection or training at either type of facilities) to 100% (all
facilities have training and inspection). The associated Cronbach’s
alpha of this scale was a=0.74. A secondary measure of human
rights monitoring was also included in analyses and reflects the
level of mental health care provided to incarcerated citizens. The
ordinal scale for this ranged from 0 (no prisons provide mental
health care) to 4 (all or most prisons—80–100%—provide mental
health care).
Domain 3: Financing. Financing for mental health care was
measured as the percentage of government health expenditures
directed towards mental health. This figure pertains to expenditures
allocated by governments’ health departments and therefore does
not include the private sector; however, in most LAMICs, public
provisions are the primary source of mental health care.
Domain 4: Human resources. Mental health infrastructure
can be thought of both in terms of physical facilities and the level
of human resources existing within facilities to care for and
monitor patients. As these measures are often highly correlated
with one another, including in the present sample, level of human
resources was utilized. The number of psychiatrists, nurses,
psychologists, social workers, and occupational therapists
working within mental health facilities (per 100,000 population)
were summed to represent the total number of specialized human
resources currently working within the field of mental health. A
secondary measure relating to human resources was also
documented—namely, the availability of treatment protocols for
mental illness in physician-based primary care settings. This
comprised a 5-point ordinal scale ranging from no availability in
primary care facilities (0%) to available in all or almost all primary
care facilities (81%–100%).
Domain 5: Advocacy. A variety of stakeholders in mental
health treatment and delivery exist outside of the formal
government. Separate measurements were created for the three
most prominent of these groups: user associations, associations
comprised of those affected by mental illness; family member
associations, associations formed by family members of those
affected by mental illness; and additional nongovernmental
organizations (NGOs). For the first two, a yes/no question
identifying whether these associations are involved in
formulation of mental health legislation was utilized. For NGOs,
the overall rate of membership per 100,000 population was used.
Outcome Measures
The term access encapsulates two interrelated concepts:
availability, which refers to the supply dimension of access, and
affordability, which refers to consumers’ financial means to
purchase the product. Separate scales, based on WHO-AIMS
responses, were created for each of these constructs.
Availability of psychotropic medicines. Availability of
psychotropic medicines is operationally defined within the WHO-
AIMS instrument as ‘‘the percentage of mental health facilities in
which there is at least one psychotropic medication of each
therapeutic category(antipsychotic, antidepressant, mood stabilizer,
anxiolytic medicines, and antiepileptic medicines) available all year
long.’’ These percentages were averaged across the four types of
mental health facilities within countries—mental hospitals,
outpatient facilities, community-based inpatient facilities, and
primary care facilities—in order that the final measure of
availability reflect all potential points of patient access [5].
Affordability of psychotropic medicines to
consumers. The affordability of psychotropic medications
comprises two components that must be integrated: first, the
cost of psychotropic medicines relative to a measurement of
consumer income, and second, an estimate of the level of
government subsidies to reduce consumer costs [55]. Regarding
the former, WHO-AIMS provides a figure for the price of the
lowest-cost generic antidepressant available within the country
relative to minimum wage. For two reasons, this value was utilized
as a proxy for medication costs. First, in part because of the higher
prevalence of major depressive disorder relative to other mental
illnesses, data on antidepressant prices are more widely
documented across countries than data on other psychotropic
medicines [56]. Second, a denominator value such as daily
minimum wage or lowest-paid government worker allows one to
observe the effect of prices on an average consumer and is a metric
available across countries [57]. In terms of government
subsidization, the percentage of the population with free access
to essential psychotropic medicines was utilized to determine how
much of the cost is carried by consumers as opposed to the
government. Final consumer costs must reflect cost to consumers
once subsidization levels are taken into account [55]. As such, cost
to consumers was multiplied by the percentage within the country
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Country or Country Region
Mean Income per
Capita (US$)
a Population
Medicine
Availability (%)
Medicine Cost (Percent
Daily Income)
AFR (Africa)
Benin 700 9,212,000 58.8 10.1
Burundi 140 8,519,000 52.5 9.9
Republic of the Congo 1,790 3,759,000 27.5 17.9
Eritrea 300 5,224,000 52.5 0.0
Ethiopia 280 84,976,000 78.5 2.3
Nigeria 1,170 158,59,000 75.0 3.2
South Africa 5,820 50,492,000 — 0.1
Uganda 420 33,796,000 57.3 0.0
AMR (Americas)
Anguilla — 14,000 22.5 0.0
Belize 3,740 313,000 97.5 0.0
Bolivia 1,460 10,031,000 69.2 21.5
Brazil 7,300 195,423,000 83.8 0.0
Chile 9,370 17,135,000 92.0 0.0
Costa Rica 6,060 4,640,000 89.8 0.9
Dominica 4,750 67,000 72.5 0.0
Dominican Republic 4,330 10,225,000 77.5 9.2
Ecuador 3,730 13,775,000 52.4 —
El Salvador 3,460 6,194,000 46.0 0.0
Guatemala 2,680 14,377,000 25.0 16.8
Guyana 1,450 761,000 97.5 0.0
Honduras 1,740 7,616,000 52.5 0.0
Jamaica 4,800 2,730,000 97.5 0.0
Nicaragua 1,080 5,822,000 41.8 3.9
Panama 6,690 3,508,000 76.2 3.3
Paraguay 2,110 6,460,000 97.5 3.6
Saint Lucia 5,410 174,000 67.1 0.0
Suriname 4,760 524,000 67.5 0.0
Uruguay 8,260 3,372,000 83.8 5.4
EMR (Eastern Mediterranean)
Afghanistan 370 29,117,000 53.0 15.9
Djibouti 1,130 879,000 52.5 —
Egypt 1,800 84,474,000 66.2 1.0
Iran 3,540 75,078,000 82.7 0.7
Morocco 2,520 32,381,000 89.9 1.6
Somalia (South Central) 150 9,119,000 44.2 1.7
Somalia (Somaliland) 150 3,000,000 — 3.2
Sudan 1,100 43,192,000 75.0 17.9
Tunisia 3,480 10,374,000 97.5 0.0
West Bank and Gaza 1,250 3,636,000 — 0.0
EUR (Europe)
Albania 3,840 3,169,000 97.5 0.0
Armenia 3,350 3,090,000 67.5 0.0
Azerbaijan 3,830 8,934,000 97.5 3.0
Georgia 2,500 4,219,000 — 6.9
Kosovo 3,910 1,900,000 — 0.0
Kyrgyzstan 780 5,550,000 91.3 0.0
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daily minimum wage needed to purchase medicine by an average
consumer.
The Human Development Index
Availability and affordability of psychotropic medicines are
related to more general measurements of a country’s development
status. For example, income per capita, life expectancy, and
average years of education are all strongly associated with one
another and negatively associated with medicine availability and
affordability. On the one hand, including a composite measure of
these, best embodied by the Human Development Index (HDI)
[58], allows for inspection of the role of different mental health
system domains while controlling for the effects of these more
general factors. This would, in turn, benefit external validity and
permit greater generalizability of results across LAMICs. On the
other hand, given that the functional integrity of health systems is
itself intrinsically related to measures like income per capita and
life expectancy, controlling for HDI may risk diminishing
ecological validity insofar as doing so creates an artificial scenario
in which HDI is exogenous to health systems measurements. To
accommodate both perspectives, regression analyses were per-
formed first without and then with HDI as a covariate.
Data Analysis
Data analysis was conducted in two phases. In the initial phase,
pairwise correlations were used to inform decisions about selection
of independent variables within each health systems’ domain.
Associations greater than 0.4 were flagged as a potential indication
of collinearity, and the variable was either removed from analyses
or integrated with its associated counterpart to represent a more
general measurement construct. For instance, the number of
psychiatrists, nurses, psychologists, social workers, and occupa-
tional therapists within a country (per 100,000 population) were
strongly associated and were therefore totaled in order to represent
the broader construct of overall human resources for mental
health. Alongside this approach, the potential for collinearity
within regression models was assessed by analyzing the variance
inflation factor (VIF) associated with individual independent
variables, for which a VIF greater than 10 is often considered
an indication of collinearity [59]. In all instances, independent
variables had VIFs less than 2.
In the second phase of data analysis, ordinary least squares
(OLS) multiple linear regression analyses were conducted using
independent variables within each mental health systems’ domain
of interest. In total, five regressions—one for each health systems’
domain—were conducted. Regressions were first run without the
HDI measurement as a covariate and then with this measurement
included. All betas reported in the results section are unstandard-
ized. For individual regression analyses, missing data were
addressed with multiple imputation analysis using STATA 11.0’s
MI command (multiple imputation suite package). This approach
considers the relationship of missing data to other observed
characteristics in the data set, thereby reducing bias, in addition to
accounting for sampling variability across imputations by
introducing an error term for each imputed value [60]. Overall,
Country or Country Region
Mean Income per
Capita (US$)
a Population
Medicine
Availability (%)
Medicine Cost (Percent
Daily Income)
Latvia 11,860 2,240,000 91.3 2.0
Moldova 1,500 3,700,000 91.3 2.1
Ukraine 3,200 45,433,000 71.4 —
Uzbekistan 910 27,794,000 83.8 0.0
SEAR (South East Asia)
Bangladesh 520 164,425,000 87.0 2.5
Bhutan 1,900 708,000 72.5 0.0
India (Gujarat) 1,040 51,000,000 77.5 —
India (Uttarakhand) 1,040 8,480,000 25.0 —
Maldives 3,640 314,000 33.8 0.0
Nepal 400 29,853,000 91.3 —
Pakistan 950 184,753,000 44.2 6.3
Sri Lanka 1,780 20,410,000 97.5 —
Thailand 3,670 68,139,000 97.5 0.1
Timor L’este 2,460 1,171,000 47.5 0.0
WPR (West Pacific)
China (Hunan) 2,940 66,977,000 87.5 —
Mongolia 1,670 2,701,000 74.0 7.5
Myanmar 580 50,496,000 91.3 6.2
Philippines 1,890 93,617,000 77.5 —
Vietnam 890 89,029,000 66.3 6.7
Total
n=63 2,750 1,886,750,000 71.3 3.6
aIncome per capita was measured using mean gross national income (GNI) per capita, Atlas Method, in 2010.
doi:10.1371/journal.pmed.1001166.t001
Table 1. Cont.
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and protocols for treatment) to 11% (total level of human
resources). All analyses were conducted in STATA/SE 11.0 at
the 0.05 alpha level. Given that multiple analyses were conducted,
it should be noted that the possible occurrence of a type 1 error
was greater than 0.05, although this was considered a necessary
limitation granted the sample size (for further discussion, see [61]).
As the response values for the availability outcome ranged from
0% to 100%, residual analysis was conducted to assess OLS
assumptions. This was done in two steps: first, studentized residuals
were inspected with quantile normal plots. At this step, no obvious
departures from normality were observed. Second, Shapiro-Wilk W
tests for normal data wereused to formally evaluate the normality of
the distribution of studentized residuals. On this measure, there was
only one instance in which this test was marginally significant
(p=0.05): namely, when availability was regressed on measures of
governance (i.e., specificity of national mental health plans and
legislation), without the inclusion of HDI as a covariate. In order to
observe the impact of this effect, a square transformation was
performed on the availability outcome, after which the Shapiro-
Wilk test was no longer significant (p.0.10). Given that regression
results did not differ considerably between the original model and
this model, the original (nontransformed) result was retained in
order to facilitate interpretability and consistency.
Results
Availability of Medicines across Facilities
Of the 63 countries in the sample, 58 provided data on
availability of medicines at all four types of mental health facilities.
On average, 71% (standard deviation [SD]=22%) of facilities had
at least one psychotropic medicine of each therapeutic category—
antipsychotic, antidepressant, mood stabilizer, anxiolytic, and
antiepileptic medicines—available. Mean availability was 70% in
low (SD=17%, n=15) and lower-middle income countries
(SD=25%, n=31), as compared to 82% (SD=10%, n=11) in
upper-middle income countries. Ten countries, all of which were
low or lower-middle income, reported that psychotropic medicines
were available in fewer than half of facilities.
Multiple regression analyses identified significant associations
with medicine availability in each of the five health systems
domains. In terms of legislation, both the specificity of national
mental health plans (b=1.27, p,0.05) and mental health laws
(b=1.65, p,0.05) were positively associated with availability.
Similarly, human rights training and inspection was related to
availability (b=0.27, p,0.01), as was the percentage of the health
budget directed towards mental health (b=3.57, p,0.05), with a
1% increase in health expenditures associated with a 3.57%
increase in availability across facilities.
Table 2. Domain-specific associations with medicine availability.
Domain Without HDI as Covariate With HDI as Covariate
Domain 1: Mental health legislation
National mental health plan b=1.27 (CI 0.13–2.41)* b=1.22 (CI 0.12–2.32)*
Formal mental health laws b=1.65 (CI 0.07–3.22)* b=1.00 (CI 20.62 to 2.63)
HDI — b=0.49 (CI 0.04–0.93)*
Overall model R
2=0.16** R
2=0.23**
Domain 2: Human rights monitoring
Human rights training/inspection b=0.27 (CI 0.08–0.46)** b=0.23 (CI 0.04–0.42)*
Mental health care for prisoners b=2.52 (CI 21.67 to 6.71) b=20.22 (CI 24.97 to 4.52)
HDI — b=0.54 (CI 0.05–1.04)*
Overall model R
2=0.15* R
2=0.23**
Domain 3: Mental health financing
Expenditures on mental health b=3.57 (CI 0.48–6.65)* b=1.99 (CI 21.32 to 5.31)
HDI — b=0.51 (CI 0.02–0.99)*
Overall model R
2=0.10* R
2=0.17**
Domain 4: Mental health infrastructure
Human resources for mental health b=0.59 (CI 20.02 to 1.20)
+ b=0.11 (CI 20.69 to 0.92)
Diagnostic/treatment protocol b=4.30 (CI 0.51–8.10)* b=3.64 (CI 20.12 to 7.41)
+
HDI — b=0.55 (CI 20.02 to 1.12)
+
Overall model R
2=0.14* R
2=0.21*
Domain 5: Mental health advocacy
User associations b=5.55 (CI 27.94 to 19.05) b=2.20 (CI 210.78 to 15.18)
Family associations b=16.73 (CI 3.74–29.72)* b=15.76 (CI 3.44–28.08)*
Other NGOs b=21.09 (CI 216.53 to 14.35) b=26.22 (CI 221.50 to 9.02)
HDI — b=0.62 (CI 0.18–1.06)**
Overall model R
2=0.16* R
2=0.29**
+p,0.10.
*p,0.05.
**p,0.01.
CI, 95% CI.
doi:10.1371/journal.pmed.1001166.t002
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of assessment and treatment protocols at the primary health care
level was related to availability (b=4.30, p,0.05); a 1-unit
increase on the ordinal scale (e.g., from 21%–50% to 51%–80%
availability of protocols) was associated with a 4.3% increase in
medicine availability. Lastly, with respect to advocacy organiza-
tions, the participation of family associations in the formation and
implementation of mental health policies was associated with a
16.7% increase in availability of psychotropic medicines
(b=16.73, p=0.01). In contrast, participation of user associations
(b=5.55, p.0.05) and other NGOs (b=21.09, p.0.05) was not
significantly related with availability. Table 2 presents an overview
of these results.
When the HDI was taken into account as a covariate, the
percent of health expenditures on mental health (b=1.99, p.0.05)
became nonsignificant as an independent variable, a finding to be
expected given that income per capita, one aspect of HDI, is
strongly associated with allocation of financing and medicine
availability. Additionally, the effect of mental health laws (b=1.00,
p.0.05) and treatment protocols (b=3.64, p.0.05) became
nonsignificant with the inclusion of HDI, although there was a
trend towards significance (p,0.10) in the latter.
Figure 1 illustrates the relationship between medicine availabil-
ity and two of the independent variables: involvement of family
associations in the formation of mental health legislation, and
access to treatment protocols for diagnosis and treatment of
mental illness at the level of primary care.
Affordability of Medicines to Consumers
Fifty-four countries provided data on affordability of psycho-
tropic medicines to consumers. While the average cost of
psychotropic medicine was 3.6% of daily income, variation in
price was considerable (SD=5.5% daily income). In total,
individuals in 26% (n=14) of respondent countries have to pay
greater than 5% of daily income, and individuals in 11% (n=6)of
countries greater than 10% of daily income. Estimated costs also
varied by income group classification: On average, purchasing
price was 4.6% of daily income in low income countries
(SD=4.7%, n=15), 4.0% in lower-middle income countries
(SD=6.7%, n=26), and 1.7% in upper-middle income countries
(SD=2.9%, n=12).
Three independent measures were significantly associated with
affordability of medicines to consumers. The overall rate of human
resources working within the mental health sector of the country
was negatively associated with cost to consumers (b=20.20,
p,0.05), with an increase of ten health workers per 100,000
population associated with a two percentage point decrease in
daily income needed to purchase medicines. Similarly, increasing
health expenditures dedicated to mental health by 1% was
associated with a 1.2% decrease in percentage daily income
needed to acquire medicine (b=21.17, p,0.01). Additionally,
availability of mental health care to prisoners was also negatively
associated with affordability (b=21.23, p=0.02). Table 3 pre-
sents an overview of these results.
Across health systems domains, no indicator variable remained
significant when HDI was included as a covariate. However, HDI
itself was strongly associated with medicine costs to consumers
(r=20.38, p,0.01) and played a significant role in regression
analyses, as such indicating the centrality of overall country
development in relation to affordability of medicines to consumers.
Figure 2 illustrates this relationship.
Discussion
To our knowledge, this is the first study to examine the
association between health systems measures and access to
psychotropic medicines across a diverse group of LAMICs. These
data indicate that access to medicines is associated with the
content of structures within countries’ mental health systems, but
also that there are distinctions between availability and afford-
ability outcomes; in particular, overall country development is
more strongly associated with affordability compared to availabil-
ity.
Availability of Psychotropic Medicines
Availability of psychotropic medicines was associated with
components within each of the five mental health systems
domains. One possible explanation for the association between
Figure 1. Medicine availability in relation to involvement of family associations and existence of treatment protocols. Countries with
family associations participating in mental health policy formation have psychotropic medicines available at 85% of facilities, as compared to ,70%
of facilities in countries without family associations. Countries with protocols in some, most, or all primary care facilities have 80% availability, as
compared to 66% availability in countries with no or few facilities with protocols in place.
doi:10.1371/journal.pmed.1001166.g001
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psychotropic medicines is that countries that place greater
emphasis on the protection of vulnerable populations, including
those with mental illness, may be more likely to consider
availability of medications among those protections deemed
necessary [62]. More generally, this finding suggests that
cultivating a public perception that patients with mental illness
deserve fundamental protections has potential to expand access to
treatment, a finding supported by the role of family associations in
promoting access (see below). However, it is also noteworthy that
the magnitude of the effect is relatively modest: a 10% increase in
training and inspection across facilities corresponds to an
estimated 2.5% increase in availability.
Greater budget allocation towards mental health was associated
with increased availability of psychotropic medicines, but this
association was mitigated in countries with low HDI. This finding
isrelativelyunsurprisinggivenpreviousresearchshowingthatpoorer
countries allocate less of their budget towards mental health [8].
Indeed, in poorer countries infectious diseases and maternal and
child health issues account for a greater percentage of morbidity and
mortality and likely affect the priority of mental health care [63].
Additionally, there is an underestimation of the magnitude of mental
health problems in LAMICs, which is compounded by stigma and
negative cultural perceptions towards these problems [64].
Within the realm of mental health legislation, the specificity of
content in mental health plans and laws were both associated with
availability; however, only the association with mental health plans
remained significant when controlling for the effect of HDI. The
more stable effect of a national plan is in accordance with the
contemporary nature of this form of legislation: While the median
year of countries’ most recent national plan revisions was 2003, the
median year of countries’ most recent law revisions was 1985. Insofar
as plans are more current, they are more liable to characterize
governments’ present efforts to strengthen their mental health
systems,irrespectiveofdevelopmentstatus.Althoughpreviousreports
have posited a conceptual link between government legislation and
expansion of access to treatment [5,6,8,65], this study reports an
empirical association at the cross-national level. Overall, a national
mental health policy that meets all 12 content specifications is
associated with 15% greater availability of medicines across facilities,
a n dm e n t a lh e a l t hl a w st h a tm e e ta l le i g h tc o n t e n ts p e c i f i c a t i o n s1 3 %
greater availability, as compared to having no legislation.
With regard to advocacy groups, only family associations—and
more specifically the involvement of family associations in shaping
the formulation of mental health legislation—were associated with
greater availability of medicines: Participation of families was
associated with a 16.5% increase in availability of medicines. In
contrast, user association involvement and the presence of NGOs
Table 3. Domain-specific associations with medicine affordability.
Domain Without HDI as Covariate With HDI as Covariate
Domain 1: Mental health legislation
National mental health plan b=0.09(CI20.25 to 0.42) b=0.12(CI20.21 to 0.44)
Formal mental health laws b=20.23 (CI 20.69 to 0.23) b=0.01(CI20.46 to 0.48)
HDI — b=20.16 (CI 20.28 to 20.04)*
Overall model R
2=0.03 R
2=0.16
+
Domain 2: Human rights monitoring
Human rights training/inspection b=20.01 (CI 20.07 to 0.04) b=20.01 (CI 20.06 to 0.05)
Mental health care for prisoners b=21.23 (CI 22.27 to 20.18)* b=20.58 (CI 21.83 to 0.68)
HDI — b=20.12 (CI 20.25 to 0.01)
+
Overall model R
2=0.11 R
2=0.17*
Domain 3: Mental health financing
Expenditures on mental health b=21.17 (CI 22.00 to 20.33)** b=20.79 (CI 21.76 to 0.13)
+
HDI — b=20.10 (CI 20.22 to 0.02)
Overall model R
2=0.15** R
2=0.19*
Domain 4: Mental health infrastructure
Human resources for mental health b=20.20 (CI 20.37 to 20.03)* b=20.08 (CI 20.31 to 0.14)
Diagnostic/treatment protocol b=20.57 (CI 21.55 to 0.41) b=20.45 (CI 21.43 to 0.53)
HDI — b=20.11 (CI 20.26 to 0.04)
+
Overall model R
2=0.12* R
2=0.16*
Domain 5: Mental health advocacy
User associations b=23.07 (CI 26.87 to 0.72) b=22.02 (CI 25.84 to 1.80)
Family associations b=0.01(CI23.50 to 3.52) b=0.14(CI23.24 to 3.52)
Other NGOs b=22.47 (CI 25.50 to 0.55) b=21.44 (CI 24.62 to 1.74)
HDI — b=20.12 (CI 20.24 to 20.01)*
Overall model R
2=0.10 R
2=0.17
+
+p,0.10.
*p,0.05.
**p,0.01.
CI, 95% CI.
doi:10.1371/journal.pmed.1001166.t003
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inasmuch as individuals who comprise them identify with those
affected by illness, but may also hold more influence than users, as
users often represent a particularly vulnerable and often
marginalized population, which may not be granted a voice to
advocate for themselves [62,66]. Furthermore, the interests and
priorities of users often differ from those of their family members
[66]. Indeed, in many instances families may value the effect of
medicines more than users, who often prefer psychosocial
treatments. However, it is unclear from our results whether users
have not been active in policy formation in general or have not
voiced a specific desire for greater access to psychotropic
medicines; further research along these lines is required.
The presence of protocols for diagnosis and treatment of mental
disorders in primary care settings was also associated with
medicine availability: The existence of protocols in all or almost
all primary care facilities correlates with 17% greater availability of
medicines, as compared to having no protocols in place. From one
perspective, protocols may serve to increase health workers’ ability
to detect and diagnose mental disorders, and in turn generate
greater demand for availability of medicines as part of treatment
[67,68]. Yet, it may also be the case that higher income countries
have the ability to supply both treatment protocols and medicines
to primary care facilities. This latter view is supported by the
finding that the association between protocols and availability is
weakened by the inclusion of HDI.
Overall, our results suggest a foundational role for health system
strengthening in promoting the availability of psychotropic
medicines: Detailed mental health legislation, involvement of
family associations in policy formation, greater allocation of
financial resources to mental health, and the existence of protocols
for diagnosis and treatment of mental disorders are all associated
with greater medicine availability.
Affordability of Psychotropic Medicines
While a variety of health systems inputs contribute to the
availability of psychotropic medicines at mental health facilities, a
more limited array of indicators was related to the affordability of
these drugs to consumers. Without taking HDI into account, only
three independent variables were significantly associated with
affordability: the percentage of health expenditures directed
towards mental health, the number of human resources working
in the field of mental health (per 100,000 population), and
availability of mental health care to prisoners.
The finding that affordability is associated with the percentage
of the health budget directed towards mental health again
highlights the central importance of allocating financial resources
towards mental health in order to broaden access, though the
effect of this is modest. Similarly, greater levels of human resources
were related to affordability, with an increase of ten mental health
workers per 100,000 population associated with a 2% decrease in
wages needed to pay for psychotropic medicines.
While both findings highlight a potential role for resource
allocation in promoting affordability, there are competing
interpretations of these results. On the one hand, greater
allocation of resources to mental health may reflect government
prioritization of treating mental illness. However, this conclusion is
challenged by the findings that neither national mental health
Figure 2. Association between HDI and affordability. HDI represents a composite measure of a country’s average life expectancy, educational
attainment, and gross domestic product per capita. The strength of this measurement’s association with affordability of psychotropic medicines is
r=20.38, p,0.01.
doi:10.1371/journal.pmed.1001166.g002
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(p.0.50). On the other hand, overall country development, as
reflected by HDI, might have a role in determining whether the
country has resources available. This finding is supported by the
role of HDI, which, when included as a covariate, contributes to
the nonsignificance of both variables (i.e., the effects of financial
and human resources) at the 0.05 alpha level.
Results also suggest a relationship between mental health care
for prisoners and affordability of medications to consumers: In
contexts where prisoners are granted greater access to mental
health care, medicines tend to be more affordable. While
speculative, it is plausible that the wealth of a country acts as a
prior determinant, whereby richer countries can both subsidize
medicines and afford mental health care for prisoners. However,
further research is required to investigate this linkage.
Irrespective of a country’s development status as measured by
HDI, the integrity of mental health systems remains associated
with availability of medicines, but not to affordability of medicines
to consumers. One principal interpretation of this result relates to
the emphasis that intergovernmental organizations like the World
Health Organization place on countries’ construction of an
essential medicines list, which promotes a modest level of essential
psychotropic medicines across countries, largely independent of
development status [69]. For this reason, factors more exogenous
to development—namely, those relating more to the functional
integrity of the countries’ mental health system—are liable to
relate to availability. In contrast, there is a less clear-cut set of
operationalized standards and strategies for how to make essential
medications affordable to consumers within countries. Therefore,
one would expect affordability to have a much more direct
relationship with country development outside the health sector.
Poorer countries that cannot afford to subsidize psychotropic
drugs may be encouraged to make drugs available to consumers,
but nevertheless the consumers may have to bear the purchasing
costs.
Consistent with the present results, other studies have similarly
demonstrated the importance of country wealth in promoting
treatment of mental disorders. For example, Large and colleagues
found a significant association between country GDP and duration
of untreated psychosis in LAMICs, whereby mean duration of
untreated psychosis fell by 6 wk for every US$1,000 of GDP
(purchasing power parity) [70]. In a similar vein, wealthier
LAMICs are more likely to publish research on mental disorders
[71]. These findings, as well as those concluded upon from this
study, underscore a common narrative: country wealth and
development appear to play central roles in promoting the mental
health research and treatment agenda of LAMICs.
In addition to the meta-level impact of HDI on affordability, it
is also important to note the wide variation in affordability scores
across countries at similar levels of HDI, as indicated by the
dispersion of data points in Figure 2. Interpreting and accounting
for this variability in future analyses will entail the acquisition of
more detailed data, the refinement of assessment tools, and a
conceptual focus on what works at the meso- and micro-levels of
health systems.
Study Limitations
Several limitations should be acknowledged. First, the number
of observations in this study is relatively small and therefore
precluded analysis of a large number of variables within each
mental health systems’ domain. This limitation was addressed, in
part, by the creation of composite measures that characterize the
broader aspects of each domain. However, one important
consequence of this is that specificity of individual associations
may be lost: for example, the relationship between total human
resources and access could be examined, but individual relation-
ships between psychiatrists, nurses, and psychologists and
outcomes of interest could not be established. Similarly, regression
analysis across health system domains could not be conducted and
would likely have contributed to significantly improved model fit.
As more countries participate in the WHO-AIMS project, such
analyses will become increasingly feasible.
Secondly, given the usage of cross-sectional data, the present
analyses cannot distinguish the directionality of individual
relationships. Associations identified in this study are helpful
insofar as they pinpoint commonalities among those health
systems with greater access to medicines. Moreover, while the
inclusion of HDI as a covariate has the effect of making
independent measures more comparable across countries, it also
risks overcontrolling for social processes, as it is not a strictly
economic measure.
Lastly, while WHO-AIMS data are collected by country focal
points using a specific set of instructions and are reviewed by
WHO headquarters, the data are still imprecise insofar as most
LAMICs do not have advanced technologies for gathering mental
health systems data. However, such imprecision would likely bias
results towards nonsignificance and therefore bolsters the validity
of associations identified here. The use of country focal points also
increases the possibility that some countries reported biased
results. In general, all countries should have a similar impetus to
bias estimates upwards. However, results from analyses would only
be affected insofar as countries that overestimate results differ in a
significant and systematic way from countries which do not and
this difference is related to the outcomes of interest, a scenario that
seems unlikely.
Conclusion
Improving access to psychotropic medicines constitutes an
essential and cost-effective component in the treatment of mental
illnesses, including mood disorders, psychotic disorders, and
anxiety disorders. We found that availability of medicines at
mental health facilities was associated with components within all
five mental health systems domains. In contrast, a limited set of
indicators was associated with affordability. While correlates of
availability remained significant when controlling for HDI, none
remained significant in relation to affordability. Results suggest
that strengthening specific mental health systems features might be
an important way to facilitate access to psychotropic medicines,
and results also underscore the differentially greater role of country
development in promoting affordability. However, given the
associational nature of these analyses and limited sample size,
future analyses should be conducted to extend the main findings of
this study. Furthermore, in light of the heterogeneity of findings
across countries at similar levels of HDI, research should continue
to identify what kinds of interventions can positively influence
affordability, including within the health sector.
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Background Mental disorders—conditions that involve
impairment of thinking, emotions, and behavior—are
extremely common. Worldwide, mental illness affects
about 450 million people and accounts for 13.5% of the
global burden of disease. About one in four people will have
a mental health problem at some time in their life. For some
people, this will be a short period of mild depression,
anxiety, or stress. For others, it will be a serious, long-lasting
condition such as schizophrenia, bipolar disorder, or major
depression. People with mental health problems need help
and support from professionals and from their friends and
families to help them cope with their illness but are often
discriminated against, which can make their illness worse.
Treatments include counseling and psychotherapy (talking
therapies), and psychotropic medicines—drugs that act
mainly on the brain. Left untreated, many people with
serious mental illnesses commit suicide.
Why Was This Study Done? About 80% of people with
mental illnesses live in low- and middle-income countries
(LAMICs) where up to 85% of patients remain untreated.
Access to psychotropic medicines, which constitute an
essential and cost-effective component in the treatment of
mental illnesses, is particularly poor in many LAMICs. To
improve this situation, it is necessary to understand what
health systems factors limit the availability and affordability
of psychotropic drugs; a health system is the sum of all the
organizations, institutions, and resources that act together to
improve health. In this cross-sectional study, the researchers
look for associations between specific health system
components and access to psychotropic medicines by
analyzing data collected from LAMICs using the World
Health Organization’s Assessment Instrument for Mental
Health Systems (WHO-AIMS). A cross-sectional study
analyzes data collected at a single time. WHO-AIMS, which
was created to evaluate mental health systems primarily in
LAMICs, is a 155-item survey that Ministries of Health and
other country-based agencies can use to collect information
on mental health indicators.
What Did the Researchers Do and Find? The researchers
used WHO-AIMS data from 63 countries/country regions and
multiple regression analysis to evaluate the role of mental
health legislation, human rights implementation, mental
health care financing, human resources, and advocacy in
shaping medicine availability and affordability. For each of
these health systems domains, the researchers developed
one or more summary measurements. For example, they
measured financing as the percentage of government health
expenditure directed toward mental health. Availability of
psychotropic medicines was defined as the percentage of
mental health facilities in which at least one psychotropic
medication for each therapeutic category was always
available. Affordability was measured by calculating the
percentage of daily minimum wage needed to purchase
medicine by the average consumer. The availability of
psychotropic medicines was related to features of all five
mental health systems domains, report the researchers.
Notably, having a national mental health plan (part of the
legislation domain) and the participation (advocacy) of
family-based organizations in mental health legislation
formulation were associated with 15% and 17% greater
availability of medicines, respectively. By contrast, only the
levels of human resources and financing, and the availability
of mental health care in prisons (part of the human rights
domain) were associated with the affordability of
psychotropic medicines. Once overall country development
was taken into account, most of the associations between
health systems factors and medicine availability remained
significant, while the associations between health systems
factors and medicine affordability were no longer significant.
In part, this was because country development was more
strongly associated with affordability and explained most of
the relationships: for example, countries with greater overall
development have higher expenditures on mental health
and greater medicine affordability compared to availability.
What Do These Findings Mean? These findings indicate
that access to psychotropic medicines in LAMICs is related to
key components within the mental health systems of these
countries but that availability and affordability are affected
to different extents by these components. They also show
that country development plays a strong role in determining
affordability but has less effect on determining availability.
Because cross-sectional data were used in this study, these
findings only indicate associations; they do not imply
causality. They are also limited by the relatively small
number of observations included in this study, by the
methods used to collect mental health systems data in many
LAMICs, and by the possibility that some countries may have
reported biased results. Despite these limitations, these
findings suggest that strengthening specific mental health
system features may be an important way to facilitate access
to psychotropic medicines but also highlight the role that
country wealth and development play in promoting the
treatment of mental disorders.
Additional Information Please access these Web sites via
the online version of this summary at http://dx.doi.org/
10.1371/journal.pmed.1001166.
N The US National Institute of Mental Health provides
information on all aspects of mental health (in English
and Spanish)
N The UK National Health Service Choices website provides
information on mental health; its Live Well feature provides
practical advice on dealing with mental health problems
and personal stories
N The UK charity Mind provides further information about
mental illness, including personal stories
N MedlinePlus provides links to many other sources of
information on mental health (in English and Spanish)
N Information on WHO-AIMS, including versions of the
instrument in several languages, and WHO-AIMS country
reports are available
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